119 related articles for article (PubMed ID: 24568906)
21. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
22. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
23. [Failure of treatment and protocol compliance in patients with acute lymphoblastic leukemia].
Tang JY; Xue HL; Gu LJ; Chen J; Pan C; Chen J; Wang YP; Ye H; Dong L; Zou JY
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):490-3. PubMed ID: 16083545
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of early treatment response in children with acute lymphoblastic leukemia: a single institution experience in Shanghai, China.
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Chen J
Zhongguo Dang Dai Er Ke Za Zhi; 2009 Jan; 11(1):5-9. PubMed ID: 19149913
[TBL] [Abstract][Full Text] [Related]
25. [Clinical research on clearance of leukemic cell during induction of remission therapy in children with precursor B cell acute lymphoblastic leukemia].
Yi ZG; Cui L; Gao C; Jin M; Zhang RD; Li ZG; Wu MY
Zhonghua Er Ke Za Zhi; 2011 Mar; 49(3):170-4. PubMed ID: 21575363
[TBL] [Abstract][Full Text] [Related]
26. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic value of minimal residual disease in childhood B-cell acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Chen J; Jiang LM; Dong L; Pan C; Ye H; Song DL; Xue HL; Tang JY; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):120-3. PubMed ID: 16732969
[TBL] [Abstract][Full Text] [Related]
29. [Clinical Features and Prognostic Factors of Children with Acute Lymphoblastic Leukemia in High-Risk Group].
Zhang SH; An FY; Xu JX; Kong LJ; He HL; Chai YH; Zhao WL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):365-370. PubMed ID: 28446276
[TBL] [Abstract][Full Text] [Related]
30. Clinical value of pre-transplant minimal residual disease in childhood lymphoblastic leukaemia: the results of the French minimal residual disease-guided protocol.
Gandemer V; Pochon C; Oger E; Dalle JH; Michel G; Schmitt C; de Berranger E; Galambrun C; Cavé H; Cayuela JM; Grardel N; Macintyre E; Margueritte G; Méchinaud F; Rorhlich P; Lutz P; Demeocq F; Schneider P; Plantaz D; Poirée M; Bordigoni P
Br J Haematol; 2014 May; 165(3):392-401. PubMed ID: 24479958
[TBL] [Abstract][Full Text] [Related]
31. [A comparison of minimal residual disease in children with acute lymphoblastic leukemia of different genetic abnormalities].
Huang SY; Jia YP; Liu GL; Zhang LP; Lu AD; Wang B
Zhongguo Dang Dai Er Ke Za Zhi; 2014 May; 16(5):494-8. PubMed ID: 24856999
[TBL] [Abstract][Full Text] [Related]
32. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
33. [Comparison of the efficacy of two chemotherapy protocols for children with TEL-AML1[STBZ] fusion gene positive acute lymphoblastic leukemia].
Wang KL; Mei YY; Cui L; Gao C; Liu FF; Zhao XX; Li WJ; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Wu MY; Zhou X; Li ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):285-90. PubMed ID: 24762993
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
35. [Dynamically monitoring minimal residual disease in acute leukemia after complete remission by multiparameter flow cytometry and its relation with prognosis].
Sun NN; Gan SL; Sun H; Zhang QT; Liu YF; Xie XS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):339-42. PubMed ID: 23628028
[TBL] [Abstract][Full Text] [Related]
36. [Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia].
Zhang YF; Chen ZM; Lou JY; Ni WM; Wang YG; Meng HT; Tong HY; Qian WB; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):814-8. PubMed ID: 22339953
[TBL] [Abstract][Full Text] [Related]
37. Day 22 of induction therapy is important for minimal residual disease assessment by flow cytometry in childhood acute lymphoblastic leukemia.
Xu XJ; Tang YM; Shen HQ; Song H; Yang SL; Shi SW; Xu WQ
Leuk Res; 2012 Aug; 36(8):1022-7. PubMed ID: 22483330
[TBL] [Abstract][Full Text] [Related]
38. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
[TBL] [Abstract][Full Text] [Related]
39. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
Nachman JB; Sather HN; Sensel MG; Trigg ME; Cherlow JM; Lukens JN; Wolff L; Uckun FM; Gaynon PS
N Engl J Med; 1998 Jun; 338(23):1663-71. PubMed ID: 9614257
[TBL] [Abstract][Full Text] [Related]
40. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
